Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)

Phase 2

Completed

Conditions: Pulmonary Arterial Hypertension
Pulmonary Hypertension

Interventions: Combination Product: Placebo delivered via INOpulse DS Device
Combination Product: Inhaled Nitric Oxide 0.025 mg/kg IBW/hr delivered via INOpulse DS Device
Combination Product: Inhaled nitric oxide 0.075 mg/kg IBW/hr delivered via INOpulse DS Device

Registration Number: NCT01457781

Lead Sponsor: Bellerophon Pulse Technologies

Brief Summary: This is a Phase 2, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Safety, Tolerability and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo as Add-on Therapy in Symptomatic Subjects with Pulmonary Arterial Hypertension (PAH).

Detailed Description: Study to determine if inhaled nitric oxide (iNO) given through a special delivery device (INOpulse® DS) is safe and efficacious in treating Pulmonary Arterial Hypertension (PAH). Medical literature and clinical experience suggests that iNO at pulsed doses of 0.013 to 0.1 mg/kg per hour for 1 month to 2+ years appears safe and suggests efficacy for the treatment of pulmonary hypertension.

There are two parts to this study. In Part 1 (week 0 to week 16), the objectives are to determine the safety, tolerability, efficacy, and exploratory objectives of two different doses of iNO delivered by a pulsed delivery device in symptomatic subjects with PAH who remain symptomatic due to PAH on approved PAH monotherapy or combination approved PAH therapy. In Part 2 (week 17 to end of study Part 2 \[EOS Part 2\]), the objective is to compile data on the long-term effects of iNO on safety, tolerability, clinical and hemodynamic measures.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 80

Inclusion Criteria

Signed informed consent form (ICF) (and assent as appropriate) prior to the initiation of any study mandated procedures or assessments
A confirmed diagnosis of Pulmonary Hypertension Group 1 (PAH) who have either idiopathic PAH (IPAH), heritable PAH, anorexigen-induced PAH, associated PAH (APAH) with connective tissue disease (CTD), APAH with repaired simple congenital systemic to pulmonary shunt (i.e., atrial septal defect [ASD], ventricular septal defect [VSD] and/or patent ductus arteriosus [PDA]; complete repair at least 1 year prior to Screening) or APAH with human immunodeficiency virus (HIV)
Confirmation of PAH diagnosis at the time of Baseline RHC according to the following definition: mPAP ≥ 25 mmHg at rest, with a concomitant mean pulmonary capillary wedge pressure (mPCWP), mean left atrial pressure (mLAP), or left ventricular end diastolic pressure (LVEDP) ≤ 15 mmHg and a PVR ≥ 240 dynes.sec/cm-5
6MWD at least 100 meters and no greater than 450 meters
The subject is receiving at least one approved PAH therapy and is clinically symptomatic from PAH (e.g., onset or increased dyspnea on exertion, dizziness, near-syncope, syncope, chest pain or peripheral edema)
Background PAH medication doses (including calcium channel blockade if being used to treat PAH) must be stable for at least 12 weeks prior to Screening
If on background conventional therapy (e.g., digoxin, diuretics, supplemental oxygen, anticoagulation), it must have been started at least 30 days prior to Screening and be on a stable dose for at least 30 days except for anticoagulation dose
If previously treated with an endothelin receptor antagonist (ERA), phosphodiesterase-5 (PDE-5) inhibitor, prostacyclin or a prostacyclin analog and is no longer on said treatment at Screening (per inclusion criteria as above), subject must have been off said treatment for > 90 days at Screening
If previously treated with a calcium channel blocker as treatment for PAH and is no longer on the calcium channel blocker treatment at Screening (per inclusion criteria as above), subject must have been off the calcium channel blocker treatment for > 90 days at Screening
Age between 16 and 80 years (inclusive)
Male height ≤ 200 cm (6'7") or Female height ≤ 210 cm (6'11")
Subjects are willing and considered in the judgment of the Investigator able to use the INOpulse DS device continuously for up to 24 hours per day
Females of childbearing potential must have a negative pre-treatment serum pregnancy test and must be on a reliable method of contraception (including double protection if appropriate, e.g., for subjects concurrently treated with bosentan therapy)

Exclusion Criteria

Subjects with known HIV infection within the past 2 years who have a history of or show any clinical or laboratory evidence of any opportunistic pulmonary disease (e.g., tuberculosis, Pneumocystis carinii pneumonia, or other pneumonias) at the time of Screening
PAH associated with portal hypertension, untreated thyroid disorders, glycogen storage disease, Gaucher's disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders or splenectomy
Any subject with unrepaired congenital heart disease or repaired congenital heart disease other than the simple congenital to systemic shunts specified in the inclusion criteria, i.e., PAH associated with non-corrected simple congenital systemic-to-pulmonary shunts, corrected simple congenital systemic-to-pulmonary shunt with residual shunt post repair, or complex systemic-to- pulmonary shunts, corrected or non-corrected, or any other complex congenital heart disease, corrected or non-corrected
PAH associated with significant venous or capillary involvement (PCWP > 15 mmHg), known pulmonary veno-occlusive disease, or pulmonary capillary hemangiomatosis
Any subject with WHO PH Groups 2, 3, 4 or 5
Left ventricular systolic dysfunction, i.e., left ventricular ejection fraction (LVEF) < 40% or left ventricular shortening fraction (LVSF) < 22%
Left ventricular diastolic dysfunction, i.e., PCWP > 15 mmHg at rest or with exercise, acute volume loading or pharmacologic testing
History of clinically significant cardiomyopathy or valvular heart disease (i.e., moderate or greater aortic insufficiency; moderate or greater aortic stenosis; or moderate or greater mitral valve disease)
Clinically significant cardiac ischemic disease requiring use of nitrates, or hospital admission for acute coronary syndrome or intervention (percutaneous coronary intervention, coronary artery stent, coronary artery bypass surgery) within the past 90 days
Down syndrome
Any subject who develops a PCWP > 20 mmHg during AVT with iNO
Systemic hypertension defined as systolic blood pressure (SBP) > 160 mmHg and/or diastolic blood pressure (DBP) > 100 mmHg persistent at Screening after a period of rest (treated or untreated)
Systemic hypotension defined as SBP < 90 mmHg persistent at Screening after a period of rest
Moderate to severe obstructive lung disease defined as both a forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) < 70% and FEV1 < 65% of predicted value (bronchodilator administration prior to testing is optional; the test should be done within 3 years for all subjects with the exception of APAH/CTD which needs to be done within 6 months prior to Screening)
Moderate to severe restrictive lung disease: total lung capacity (TLC) < 60% of predicted; if TLC 60% to 70% predicted, a high resolution CT scan showing diffuse disease or more than mild patchy disease (done within 3 years for all subjects with the exception of APAH/CTD which needs to be done within 6 months prior to Screening)
Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C
Estimated creatinine clearance < 30 mL/min (Cockcroft-Gault formula)
Hemoglobin < 10 gm/dL at Screening or Baseline
Acute or chronic physical impairment (other than dyspnea due to PAH) that would limit the ability to comply with study procedures or adherence to therapy, including carrying and wearing the INOpulse device per study protocol
Pregnant or breast-feeding at Screening
Administered L-arginine within 30 days prior to Screening
Known concomitant life-threatening disease with a life expectancy less than 1 year
Recently started (< 12 weeks prior to randomization) or planned cardiopulmonary rehabilitation program to start within the 16 week controlled study
Atrial septostomy within 3 months of randomization
Any subject with PAH who is treatment naïve or receiving any unapproved therapy as their only PAH treatment (including calcium channel blockade if the calcium channel blockade is the only treatment for the PAH)
Any subject who requires the use of a continuous positive airway pressure (CPAP), bilevel positive airway pressure (BiPAP), or other positive pressure devices to treat obstructive sleep apnea
Medical problem(s) likely to preclude completion of Part 1
Use of investigational drugs or devices within 30 days prior to enrollment into the study (other than acute vasodilator testing with iNO or IV epoprostenol)
Any underlying medical or psychiatric condition that, in the opinion of the Investigator, makes the subject an unsuitable candidate for the study
Any condition other than the subject's PAH that, in that opinion of the investigator, affects their ability to perform the 6MWT
Refusal to follow the protocol, including the two RHCs in Part 1 and one RHC in Part 2
Unable to travel to the investigational site for all required study visits and for all additional visits per the judgment of the Investigator or Sponsor

Study & Design

Study Type: INTERVENTIONAL

Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
placebo	Placebo delivered via INOpulse DS Device	Placebo 0.075 mg/kg IBW/hr for up to 24 hours/day x 16 weeks\* (99.999% Nitrogen \[N2\] mini-cylinder; change q 24 hours) delivered via INOpulse® DS delivery device.
0.025 mg inhaled nitric oxide	Inhaled Nitric Oxide 0.025 mg/kg IBW/hr delivered via INOpulse DS Device	Inhaled nitric oxide (iNO) 0.025 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (3.0 mg/L \[2440 ppm\] NO mini-cylinder; change q 24 hours) delivered via INOpulse® DS delivery device.
0.075 mg inhaled nitric oxide	Inhaled nitric oxide 0.075 mg/kg IBW/hr delivered via INOpulse DS Device	Inhaled nitric oxide (iNO) 0.075 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (6.0 mg/L \[4880 ppm\] NO mini-cylinder; change q 24 hours) delivered via INOpulse® DS delivery device.

Primary Outcome Measures

Name	Time	Method
The primary endpoint is change in pulmonary vascular resistance (PVR) (dynes. sec/cm-5) from baseline to EOS Part 1.	baseline to Week 16	Change from Baseline to 18 weeks in PVR

Secondary Outcome Measures

Name	Time	Method
Change in 6 minute walk distance (6MWD) from baseline to EOS Part 1	baseline to Week 16	6MWT Change from Baseline to Week 16
Time (in days) to first clinical worsening event (TTCW) from randomization to EOS Part 1	randomization to Week 16	Time (in days) to first clinical worsening event (TTCW) from randomization to EOS Part 1
Change in World Health Organization (WHO) Functional Class from baseline to EOS Part 1	baseline to Week 16	WHO Functional Class Change from Baseline to Week 16
Change in Borg Dyspnea Score (BDS) from baseline to EOS Part 1	baseline to Week 16	BDS change in Baseline to Week 16
Change in patient reported outcome (PRO) scores by the SF-36 short form version 2 and the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) from baseline to EOS Part 1	baseline to Week 16	Patient Reported Outcome change from Baseline to Week 16

Trial Locations

Locations (51): Christiana Care Health System
🇺🇸
Newark, Delaware, United States
University of Florida College of Medicine
🇺🇸
Jacksonville, Florida, United States
Dartmouth-Hitchcock Medical Center
🇺🇸
Lebanon, New Hampshire, United States
LSUHSC-New Orleans
🇺🇸
New Orleans, Louisiana, United States
University of Michigan
🇺🇸
Ann Arbor, Michigan, United States
Peter Lougheed Center
🇨🇦
Calgary, Alberta, Canada
Tufts Medical Center
🇺🇸
Boston, Massachusetts, United States
Boston University Medical Center/Boston University School of Medicine
🇺🇸
Boston, Massachusetts, United States
West Los Angeles VA Healthcare Center
🇺🇸
Los Angeles, California, United States
Barnabas Health Newark Beth Israel Medical Center
🇺🇸
Newark, New Jersey, United States
University of Maryland Medical Center
🇺🇸
Baltimore, Maryland, United States
University of Medicine and Dentistry of NJ
🇺🇸
Newark, New Jersey, United States
Temple University Hospital
🇺🇸
Philadelphia, Pennsylvania, United States
University Health Network - Toronto General Hospital
🇨🇦
Toronto, Ontario, Canada
David Geffen School of Medicine at UCLA
🇺🇸
Los Angeles, California, United States
University of Minnesota, Cardiovascular Division
🇺🇸
Minneapolis, Minnesota, United States
Duke University Medical Center
🇺🇸
Durham, North Carolina, United States
South Denver Cardiology Associates P.C.
🇺🇸
Littleton, Colorado, United States
Children's Hospital Colorado
🇺🇸
Aurora, Colorado, United States
Washington University School of Medicine
🇺🇸
Saint Louis, Missouri, United States
Arizona Pulmonary Specialists
🇺🇸
Phoenix, Arizona, United States
University of Alabama at Birmingham
🇺🇸
Birmingham, Alabama, United States
South Oklahoma Heart Research LLC
🇺🇸
Oklahoma City, Oklahoma, United States
University of California, San Francisco-Fresno
🇺🇸
Fresno, California, United States
Los Angeles Biomedical Research Institute at Harbor-UCLA Med Ctr
🇺🇸
Torrance, California, United States
University of Colorado Denver
🇺🇸
Aurora, Colorado, United States
Cleveland Clinic Florida
🇺🇸
Weston, Florida, United States
University of Iowa Hospitals & Clinics
🇺🇸
Iowa City, Iowa, United States
Kentuckiana Pulmonary Associates
🇺🇸
Louisville, Kentucky, United States
Emory University Hospital-Emory Clinic
🇺🇸
Atlanta, Georgia, United States
University of Kansas Medical Center
🇺🇸
Kansas City, Kansas, United States
University of Kentucky Gill Heart
🇺🇸
Lexington, Kentucky, United States
Mayo Clinic
🇺🇸
Rochester, Minnesota, United States
Beth Israel Medical Center
🇺🇸
New York, New York, United States
Weill Cornell Medical Center
🇺🇸
New York, New York, United States
UC Health/University of Cincinnati
🇺🇸
Cincinnati, Ohio, United States
University Hospitals Case Medical Center
🇺🇸
Cleveland, Ohio, United States
Legacy Medical Group - Pulmonary Clinic
🇺🇸
Portland, Oregon, United States
Allegheny Singer Research Institute/Allegheny General Hospital
🇺🇸
Pittsburgh, Pennsylvania, United States
Baylor College of Medicine
🇺🇸
Houston, Texas, United States
Allianz Research Institute, Inc.
🇺🇸
Fountain Valley, California, United States
Cleveland Clinic
🇺🇸
Cleveland, Ohio, United States
Ohio State University Martha Morehouse Medical Pavillion
🇺🇸
Columbus, Ohio, United States
University of Texas Southwestern Medical Center
🇺🇸
Dallas, Texas, United States
Sioux Falls Cardiovascular PC
🇺🇸
Sioux Falls, South Dakota, United States
Aurora St. Luke's Medical Center
🇺🇸
Milwaukee, Wisconsin, United States
Intermountain Medical Center
🇺🇸
Murray, Utah, United States
London Health Sciences Centre
🇨🇦
London, Ontario, Canada
ABACUS - University of Alberta Hospitals
🇨🇦
Edmonton, Alberta, Canada
Montefiore Medical Center
🇺🇸
Bronx, New York, United States
Rhode Island Hospital
🇺🇸
Providence, Rhode Island, United States